PURPOSE To provide evidence-based recommendations to practicing clinicians on
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …

Lung cancer is one of the most common cancer in the world. In 2018, there were over 2
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …

Background Among patients with resected, epidermal growth factor receptor (EGFR)–
mutated, stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Background Osimertinib is standard-of-care therapy for previously untreated epidermal
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer …

Purpose: We assessed whether perioperative circulating tumor DNA (ctDNA) could be a
biomarker for early detection of molecular residual disease (MRD) and prediction of …

METHODS From September 2011 to April 2014, 222 patients from 27 sites were randomly
assigned 1: 1 to adjuvant gefitinib (n= 111) or VP (n= 111). Patients with resected stage II …

Lung cancer remains the leading cause of cancer deaths in the United States. In the past
decade, significant advances have been made in the science of non–small cell lung cancer …

Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …

Background Icotinib has provided survival benefits for patients with advanced, epidermal
growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). We aimed to …